ClinicalTrials.gg
RecruitingNCT02791152SingHEARTUpdated Nov 17, 2026

Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People

An observational study in Cardiovascular Diseases and Metabolic Disease, sponsored by National Heart Centre Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Heart Centre Singapore · Observational

How we know

Updated Nov 17, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
21 Years to 69 Years
Sex
All
01

Study summary

A prospective cohort of relatively healthy individuals, using comprehensive clinical information, advanced imaging (including cardiac MRI), cardiovascular exercise physiology, metabolomics and genetic analysis. These findings will be correlated with adverse clinical outcomes including death, stroke and myocardial infarction. In selected cases, follow-up imaging and biomarker samples will also be obtained. These studies will enable us to begin to address a critical gap in our knowledge as to how best to interpret the very large amount of cardiovascular tests done in Singapore and how to better to predict outcomes and manage healthcare costs in our local populations

Read the detailed description

SingHEART sub-study will collect the following data types or perform the following investigations:

  1. Demographic and clinical characteristics data
  2. Basic blood investigations.
  3. Blood analysis for blood-based biomarker, genetic, molecular, cellular or other laboratory tests during the course of the study.
  4. Perform a single baseline cardiac MRI (already consented and obtained as part of the primary study)
  5. ECG
  6. Calcium score
  7. Biobanking (whole blood, and serum, already performed as part of the primary study)
  8. Exercise and physical activity tracker for 5 to 7 days
  9. Ambulatory BP monitoring for at least 24-48 hours
  10. Continuous ECG monitoring over 1-7 days
  11. Non-mydriatic retinal imaging
  12. Grip Strength Measurement
  13. Optional: Stool sampling
  14. Optional: Long term tracking of physiology physical activities via digital platform
  15. Optional: Nasal cell collection
  16. Optional: Collection of Digital oral images
  17. Optional: Exercise and physical activity tracker for approximately 1 month (instead of the usual 5-7 days)
  18. Optional: Facial Image and Voice Recording
  19. Questionnaire on lifestyle habits (eg. diet, exercise), quality-of-life, knowledge, attitudes, practices, body constitution and psychometry at baseline, 10th and 20th year follow up
  20. Fatmass measurement at 10th and 20th year follow up only
  21. Short Performance Physical Battery (SPPB) , augmented with inertial motion units (IMU) at 10th and 20th year follow up only
  22. Any laboratory test findings and imaging studies data will be collected (e.g. echocardiography, electrocardiography (ECGs), X-rays, CT scans, MRI scans, ultrasound studies). Follow up outcome data such as hospital admission, medication use and investigations.
02

Conditions studied

  • Cardiovascular Diseases
  • Metabolic Disease
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

National Heart Centre Singapore is the lead sponsor of 63 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy volunteers age between 21 to 69 years old, Singapore citizens

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women age 21-69 years

Exclusion criteria

Exclusion Criteria:

  1. Previous myocardial infarction (MI). This will include ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI)
  2. Known coronary artery disease - prior coronary revascularization
  3. Known documented peripheral arterial disease
  4. Previous stroke

    a. Stroke is defined as new focal neurological deficit persisting more than 24hours21.

  5. More than ongoing use of 2 or more anti-hypertensive agents
  6. Prior history of cancer (excludes pre-cancerous lesions)
  7. Expected less than 1 year
  8. Known definite diabetes mellitus or on treatment for diabetes mellitus
  9. Known disease or genetic disease
  10. Known endocrine disease on treatment
  11. Psychiatric illness
  12. Asthma or chronic lung disease requiring long term medications or oxygen
  13. Chronic infective disease, including tuberculosis, and C; and
  14. Inability to comply with study protocol
  15. Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. First cardiovascular event

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bylstra Y, Lim WK, Teo JX, Menezes M, Hodgson J, Yap F, Chambers JC, Yeo KK, Tan P, Amor DJ, Jamuar SS. Unexpected genotypes associated with severe paediatric conditions identified in a healthy population cohort. Eur J Hum Genet. 2026 Mar;34(3):368-378. doi: 10.1038/s41431-025-02009-2. Epub 2026 Jan 10. PubMed 41520097 ↗
  • Bylstra Y, Lim WK, Kam S, Tham KW, Wu RR, Teo JX, Davila S, Kuan JL, Chan SH, Bertin N, Yang CX, Rozen S, Teh BT, Yeo KK, Cook SA, Jamuar SS, Ginsburg GS, Orlando LA, Tan P. Family history assessment significantly enhances delivery of precision medicine in the genomics era. Genome Med. 2021 Jan 7;13(1):3. doi: 10.1186/s13073-020-00819-1. PubMed 33413596 ↗

Individual participant data

Plan to share: Yes

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Oct 2015, a primary completion of Dec 2046 and a completion of Dec 2046. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2036 → Dec 2046 and completion Dec 2036 → Dec 2046.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2016
First posted
Jun 6, 2016
Start
Oct 2015
Primary completionEst.
Dec 2046was Dec 2036
CompletionEst.
Dec 2046was Dec 2036
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2036→Dec 2046
Nov 17, 2026
Study completion
Dec 2036→Dec 2046
Nov 17, 2026
Enrollment
1000→2000
Nov 17, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41520097 ↗
Nov 17, 2026
Contact
Study contact changed: •••8963→k•••@nhcs.com.sg · •••2275; •••2295→none listed. See the current contact
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Heart Centre Singapore · Singapore, SingaporeContact •••8963→k•••@nhcs.com.sg · •••2275
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41520097 ↗
    Primary completion Dec 2036→Dec 2046
    Study completion Dec 2036→Dec 2046
    Enrollment 1000→2000
    Contact Study contact changed: •••8963→k•••@nhcs.com.sg · •••2275; •••2295→none listed. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Heart Centre Singapore · Singapore, SingaporeContact •••8963→k•••@nhcs.com.sg · •••2275
    + 4 other changes: verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02791152
Lead sponsor
National Heart Centre Singapore
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
Oct 2015
Primary completion
Dec 2046 (estimated)
Completion
Dec 2046 (estimated)
Last update
Nov 17, 2026

Study contacts

Siew Ching Kong
Contact
kong.siew.ching@nhcs.com.sg
67042275
Khung Keong Yeo, MBBS
Contact
Yeo Khung Keong, MBBS
principal investigator · National Heart Centre Singapore

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion